Liposomal doxorubicin works by utilizing the unique properties of liposomes. These nanocarriers can encapsulate hydrophilic and hydrophobic drugs, protecting them from degradation and promoting their stability. Upon administration, liposomes circulate longer in the bloodstream, allowing for enhanced accumulation in tumor tissues via the enhanced permeability and retention (EPR) effect. Once at the tumor site, doxorubicin is released, inducing apoptosis in cancer cells.
